Dekorationsartikel gehören nicht zum Leistungsumfang.
Sprache:
Englisch
107,95 €
Versandkostenfrei per Post / DHL
Lieferzeit 1-2 Wochen
Kategorien:
Beschreibung
If you're a biotech executive, investor, deal maker, entrepreneur, or adviser—or aspire to be one—then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs.
THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.
• Vetted benchmarks for key drivers of income, expenses, and valuation.
• Proprietary analyses by Pharmagellan's experienced consulting team.
• More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.
Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.
THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.
• Vetted benchmarks for key drivers of income, expenses, and valuation.
• Proprietary analyses by Pharmagellan's experienced consulting team.
• More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.
Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.
If you're a biotech executive, investor, deal maker, entrepreneur, or adviser—or aspire to be one—then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs.
THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.
• Vetted benchmarks for key drivers of income, expenses, and valuation.
• Proprietary analyses by Pharmagellan's experienced consulting team.
• More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.
Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.
THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.
• Vetted benchmarks for key drivers of income, expenses, and valuation.
• Proprietary analyses by Pharmagellan's experienced consulting team.
• More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.
Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.
Details
| Erscheinungsjahr: | 2017 |
|---|---|
| Fachbereich: | Allgemeines |
| Genre: | Importe, Wirtschaft |
| Rubrik: | Recht & Wirtschaft |
| Medium: | Taschenbuch |
| Inhalt: | Kartoniert / Broschiert |
| ISBN-13: | 9780998407500 |
| ISBN-10: | 099840750X |
| Sprache: | Englisch |
| Einband: | Kartoniert / Broschiert |
| Autor: |
David, Frank S.
Robey, Seth Matthews, Andrew |
| Hersteller: | Pharmagellan, LLC |
| Verantwortliche Person für die EU: | Libri GmbH, Europaallee 1, D-36244 Bad Hersfeld, gpsr@libri.de |
| Maße: | 229 x 152 x 8 mm |
| Von/Mit: | Frank S. David (u. a.) |
| Erscheinungsdatum: | 06.01.2017 |
| Gewicht: | 0,212 kg |